Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.
DOI: 10.1016/j.siny.2018.02.006; PMCID: PMC6098727
Patent ductus arteriosus (PDA) is a frequent, complex, and difficult to treat clinical syndrome among preterm infants in the neonatal intensive care unit. In addition to known clinical risk factors, there are emerging data about genetic predisposition to PDA in both animal and human models. Clinical response and toxicity from drugs used to treat PDA are highly variable. Developmental and genetic aspects of pharmacokinetics and pharmacodynamics influence exposure and response to pharmacologic therapies. Given the variable efficacy and toxicity of known drug therapies, novel therapeutic targets for PDA treatment offer the promise of precision medicine. This review addresses the known genetic contributions to prolonged ductal patency, variability in response to drug therapy for PDA, and potential novel drug targets for future PDA treatment discovery.
Seminars in fetal & neonatal medicine
Acetaminophen; Animals; Disease Models, Animal; Ductus Arteriosus, Patent; Genetic Predisposition to Disease; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Pharmacogenetics
Ductus arteriosus; Genetic predisposition; Infant; Newborn
Lewis TR, Shelton EL, Van Driest SL, Kannankeril PJ, Reese J. Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment. Semin Fetal Neonatal Med. 2018;23(4):232-238. doi:10.1016/j.siny.2018.02.006